AbCellera Biologics, Inc. ABCL 深 沪
已收盘 04-02 16:00:00 美东时间
3.52
+0.010
+0.28%
华盛通- 最 高3.625
- 今 开3.43
- 成交量 349.04万股
- 最 低 3.41
- 昨 收 3.51
- 总市值 10.67亿
- 52周最高 6.515
- 市盈率 静 --
- 换手率 1.15%
- 52周最低 1.94
- 委 比 23.89%
- 总股本 3.03亿
- 历史最高 71.91
- 量 比 1.50
- 振 幅 6.13%
- 历史最低 1.8906
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Prelude Therapeutics reported financial results for 2025, highlighting a cash runway extending into Q2 2027. The company announced FDA clearance for its mutant-selective JAK2V617F inhibitor PRT12396 and plans to initiate Phase 1 trials for PRT12396 in high-risk PV and MF patients in Q2 2026. Additionally, the KAT6A degrader PRT13722 is expected to enter clinical development later in 2026. Notably, R&D expenses decreased, reflecting reduced costs ...
03-10 11:01
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts
Abcellera Biologics, Inc. (($ABCL)) has held its Q4 earnings call. Read on for ...
02-26 08:26
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Axon Enterprise Inc (NASDAQ:AXON) rose sharply in pre-market trading ...
02-25 17:22
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
02-25 16:51
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know
The Q4 earnings report for AbCellera Biologics (NASDAQ:ABCL) was released on Tu...
02-25 05:22
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
SoftBank adds TwentyOne Capital, exits Nvidia, boosts eToro stake among top Q4 trades
SoftBank Group (SFTBF) (SFTBY) added new stakes in TwentyOne Capital (XXI), closed out its holding in Nvidia (NVDA), increased its stake in trading platform eToro Group (ETOR), and pared its holding i...
02-18 00:39
AbCellera Doses First Participants In Phase 2 Portion Of Its Phase 1/2 Clinical Study For ABCL635 To Treat Moderate-To-Severe Vasomotor Symptoms Associated With Menopause
AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class non-hormonal treatment
01-12 22:10
AbCellera Strikes Patent License Deal With Bruker; Bruker To Pay $36M As Future Royalty Payments On Sales Of Beacon Optofluidic Platform Globally
AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally. As part of the
2025-12-18 22:09
AbCellera Appoints Dr. Stephen Quake to Board
AbCellera Biologics ( ($ABCL) ) has issued an announcement. On November 10, 202...
2025-11-13 03:17
